Trial Profile
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Dinutuximab beta (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 10 Oct 2023 Results assessing the efficacy and safety of long-term, continuous infusion of dinutuximab beta in patients with relapsed/refractory neuroblastoma, published in the British Journal of Cancer.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 08 Oct 2021 This trial has been completed in Austria (End Date: 10 Aug 2021), according to European Clinical Trials Database record.